Medgenics Inc. Common Stock (MDGN) 8.00 $MDGN
Insider Buys And Sells: Sprint, Graham Holdings
Asif Suria - at Seeking Alpha - Tue Mar 03, 1:45AM CST
Welcome to edition 245 of Insider Weekends. Insider buying tripled last week with insiders buying $168.17 million of stock compared to $56.56 million in the week prior. Selling on the other hand decreased with insiders selling $1.53 billion of stock...
RAX: 53.63 (-0.27), CRR: 32.05 (+0.52), MDGN: 8.00 (-0.45), S: 4.95 (-0.04), MRC: 11.89 (+0.41), DD: 74.34 (-0.17), TWTR: 48.44 (+0.51), PPG: 229.06 (+2.89), GHC: 1,085.05 (+6.36), LEA: 111.97 (+1.28)
Medgenics to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Mar 02, 3:01PM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at two upcoming investor conferences. Details of the conferences are as follows:
MDGN: 8.00 (-0.45)
5 Stocks Insiders Love Right Now: GE, Mondelez and More
at The Street - Wed Feb 25, 6:00AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
GE: 25.40 (+0.07), ADXS: 12.54 (+0.14), MDLZ: 34.74 (+0.08), MDGN: 8.00 (-0.45), MDAS: 19.52 (+0.09)
InsiderInsights.com Daily Round Up 2/23/15: MDLZ, GPRO, MDGN, CRR
InsiderInsights - at Seeking Alpha - Tue Feb 24, 6:07AM CST
GPRO: 40.40 (+0.87), LDRH: 37.76 (+0.09), MDLZ: 34.74 (+0.08), HCOM: 26.13 (+0.08), CRR: 32.05 (+0.52), MDGN: 8.00 (-0.45), DEI: 30.37 (+1.14), WETF: 22.23 (+1.22), BBY: 40.79 (-0.81), AON: 99.30 (+0.39), GOOG: 560.36 (+2.37), LEA: 111.97 (+1.28), AJX: 14.25 (-0.16), PLAY: 32.16 (-0.06), CTSH: 64.06 (-0.19), BLPH: 11.10 (+0.32), OMI: 34.20 (+0.03)
Seeking Alpha's Biotech Weekly: Sanofi's New Chief, Sarissa Shakes Ariad, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 475.98 (+42.33), BMRN: 125.17 (-2.32), CVM: 1.11 (unch), MDGN: 8.00 (-0.45), PFE: 34.25 (+0.10), SGMO: 17.63 (-0.91), RPRX: 8.98 (-0.26), MNKD: 5.26 (-0.28), CELG: 128.50 (+3.17), SGEN: 38.86 (-0.83), TEVA: 62.10 (+0.55), ARIA: 8.69 (-0.28), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Medgenics' TARGT Therapy Continues To Show Promising Clinical Results
Brian Marckx, CFA - at Seeking Alpha - Tue Feb 17, 11:15AM CST
MDGN: 8.00 (-0.45)
Medgenics' (MDGN) CEO Mike Cola on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 13, 1:26PM CST
MDGN: 8.00 (-0.45)
Medgenics FY14 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:29AM CST
MDGN: 8.00 (-0.45)
Medgenics reports Q4 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:05AM CST
MDGN: 8.00 (-0.45)
Medgenics to Host Conference Call to Announce Fourth Quarter and Full Year 2014 Results on February 13, 2015
GlobeNewswire - Fri Jan 30, 7:36AM CST
Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Friday, February 13, 2015 at 8:30 a.m. ET to discuss fourth quarter and full year 2014 financial results.
MDGN: 8.00 (-0.45)
Should You Purchase Medgenics After Its Recent Run Up?
Diamond Technology Management - at Seeking Alpha - Wed Jan 28, 11:13AM CST
MDGN: 8.00 (-0.45)
Medgenics to Present at Biotech Showcase 2015 Conference
GlobeNewswire - Thu Jan 08, 7:50AM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at the Biotech Showcase 2015 Conference in San Francisco, CA.
MDGN: 8.00 (-0.45)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 4:36PM CST
RICE: 19.84 (+0.22), FRPT: 18.31 (-0.16), KGC: 2.42 (+0.06), AUQ: 2.99 (+0.01), MDGN: 8.00 (-0.45), JNUG: 20.45 (+2.15), FOMX: 10.00 (+0.10), MRD: 17.70 (+0.02), KOS: 8.24 (-0.11), YUM: 79.21 (+0.47)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:45AM CST
LGCY: 10.02 (-0.26), PFIE: 1.30 (-0.04), MCEP: 5.43 (+0.14), MDGN: 8.00 (-0.45), LQDT: 9.62 (-0.02), AXPW: 0.06 (-0.01), PRTK: 30.83 (+0.46), BSI: 2.85 (+0.09), DRIV: 25.99 (+0.06), CBST: 101.94 (+0.14), QTWW: 2.35 (+0.12), CALA: 15.75 (+1.68), MPO: 0.85 (-0.05), SNSS: 2.60 (-0.04), CTP: 6.17 (+0.02), LPX: 16.45 (+0.23), SAEX: 3.14 (+0.32), DRYS: 0.80 (+0.07), VPCO: 1.13 (-0.03), XLRN: 41.82 (-0.62)
InsiderInsights.com Daily Round Up 12/2/14: CINF, MDGN, AVID, NHF
InsiderInsights - at Seeking Alpha - Wed Dec 03, 6:11PM CST
BTF: 27.34 (+0.45), A: 42.21 (unch), MDGN: 8.00 (-0.45), NU: 52.54 (+1.31), BBY: 40.79 (-0.81), SPB: 93.33 (+0.02), MAR: 84.04 (-0.27), AVID: 15.02 (+0.75), CINF: 54.60 (+0.81), MPC: 102.26 (+2.20), NHF: 12.13 (+0.05), EPM: 5.85 (+0.09), EMC: 26.70 (+0.49), DNY: 21.22 (+0.30), MC: 30.55 (-0.14), TWI: 9.22 (+0.01), SFXE: 4.30 (+0.14), CSCO: 28.44 (+0.18)
Medgenics Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock
GlobeNewswire - Mon Dec 01, 3:02PM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and the patient's own tissue for the treatment of rare and orphan diseases, today announced the completion of an underwritten public offering of 5,893,750 shares of its common stock, including 768,750 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Medgenics at a price to the public of $4.10 per share. The gross proceeds from this offering to Medgenics were approximately $24.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Medgenics.
MDGN: 8.00 (-0.45)
Medgenics proposes public offering of common shares
M2 - Wed Nov 26, 6:59AM CST
Gene therapy platform Medgenics (NYSE MKT:MDGN) said on Tuesday that it plans to offer and sell shares of its common stock in an underwritten public offering.
MDGN: 8.00 (-0.45)
Medgenics to Present at 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:01PM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will participate in a fireside chat discussion at the 26 Annual Piper Jaffray Healthcare Conference in New York.
MDGN: 8.00 (-0.45)
Insider Buys And Sells: Sprint, Graham Holdings
Asif Suria - at Seeking Alpha - Tue Mar 03, 1:45AM CST
Welcome to edition 245 of Insider Weekends. Insider buying tripled last week with insiders buying $168.17 million of stock compared to $56.56 million in the week prior. Selling on the other hand decreased with insiders selling $1.53 billion of stock...
RAX: 53.63 (-0.27), CRR: 32.05 (+0.52), MDGN: 8.00 (-0.45), S: 4.95 (-0.04), MRC: 11.89 (+0.41), DD: 74.34 (-0.17), TWTR: 48.44 (+0.51), PPG: 229.06 (+2.89), GHC: 1,085.05 (+6.36), LEA: 111.97 (+1.28)
Medgenics to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Mar 02, 3:01PM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at two upcoming investor conferences. Details of the conferences are as follows:
MDGN: 8.00 (-0.45)
5 Stocks Insiders Love Right Now: GE, Mondelez and More
at The Street - Wed Feb 25, 6:00AM CST
Insiders at these companies have been scooping up shares of their own stock lately.
GE: 25.40 (+0.07), ADXS: 12.54 (+0.14), MDLZ: 34.74 (+0.08), MDGN: 8.00 (-0.45), MDAS: 19.52 (+0.09)
InsiderInsights.com Daily Round Up 2/23/15: MDLZ, GPRO, MDGN, CRR
InsiderInsights - at Seeking Alpha - Tue Feb 24, 6:07AM CST
GPRO: 40.40 (+0.87), LDRH: 37.76 (+0.09), MDLZ: 34.74 (+0.08), HCOM: 26.13 (+0.08), CRR: 32.05 (+0.52), MDGN: 8.00 (-0.45), DEI: 30.37 (+1.14), WETF: 22.23 (+1.22), BBY: 40.79 (-0.81), AON: 99.30 (+0.39), GOOG: 560.36 (+2.37), LEA: 111.97 (+1.28), AJX: 14.25 (-0.16), PLAY: 32.16 (-0.06), CTSH: 64.06 (-0.19), BLPH: 11.10 (+0.32), OMI: 34.20 (+0.03)
Seeking Alpha's Biotech Weekly: Sanofi's New Chief, Sarissa Shakes Ariad, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 20, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 475.98 (+42.33), BMRN: 125.17 (-2.32), CVM: 1.11 (unch), MDGN: 8.00 (-0.45), PFE: 34.25 (+0.10), SGMO: 17.63 (-0.91), RPRX: 8.98 (-0.26), MNKD: 5.26 (-0.28), CELG: 128.50 (+3.17), SGEN: 38.86 (-0.83), TEVA: 62.10 (+0.55), ARIA: 8.69 (-0.28), SNY: 50.64 (+1.17), REGN: 488.87 (+2.85)
Medgenics' TARGT Therapy Continues To Show Promising Clinical Results
Brian Marckx, CFA - at Seeking Alpha - Tue Feb 17, 11:15AM CST
MDGN: 8.00 (-0.45)
Medgenics' (MDGN) CEO Mike Cola on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Feb 13, 1:26PM CST
MDGN: 8.00 (-0.45)
Medgenics FY14 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:29AM CST
MDGN: 8.00 (-0.45)
Medgenics reports Q4 results
Seeking Alpha - at Seeking Alpha - Fri Feb 13, 7:05AM CST
MDGN: 8.00 (-0.45)
Medgenics to Host Conference Call to Announce Fourth Quarter and Full Year 2014 Results on February 13, 2015
GlobeNewswire - Fri Jan 30, 7:36AM CST
Medgenics, Inc. (NYSE:MDGN) will host a conference call and live audio webcast on Friday, February 13, 2015 at 8:30 a.m. ET to discuss fourth quarter and full year 2014 financial results.
MDGN: 8.00 (-0.45)
Should You Purchase Medgenics After Its Recent Run Up?
Diamond Technology Management - at Seeking Alpha - Wed Jan 28, 11:13AM CST
MDGN: 8.00 (-0.45)
Medgenics to Present at Biotech Showcase 2015 Conference
GlobeNewswire - Thu Jan 08, 7:50AM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will present at the Biotech Showcase 2015 Conference in San Francisco, CA.
MDGN: 8.00 (-0.45)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 4:36PM CST
RICE: 19.84 (+0.22), FRPT: 18.31 (-0.16), KGC: 2.42 (+0.06), AUQ: 2.99 (+0.01), MDGN: 8.00 (-0.45), JNUG: 20.45 (+2.15), FOMX: 10.00 (+0.10), MRD: 17.70 (+0.02), KOS: 8.24 (-0.11), YUM: 79.21 (+0.47)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:45AM CST
LGCY: 10.02 (-0.26), PFIE: 1.30 (-0.04), MCEP: 5.43 (+0.14), MDGN: 8.00 (-0.45), LQDT: 9.62 (-0.02), AXPW: 0.06 (-0.01), PRTK: 30.83 (+0.46), BSI: 2.85 (+0.09), DRIV: 25.99 (+0.06), CBST: 101.94 (+0.14), QTWW: 2.35 (+0.12), CALA: 15.75 (+1.68), MPO: 0.85 (-0.05), SNSS: 2.60 (-0.04), CTP: 6.17 (+0.02), LPX: 16.45 (+0.23), SAEX: 3.14 (+0.32), DRYS: 0.80 (+0.07), VPCO: 1.13 (-0.03), XLRN: 41.82 (-0.62)
InsiderInsights.com Daily Round Up 12/2/14: CINF, MDGN, AVID, NHF
InsiderInsights - at Seeking Alpha - Wed Dec 03, 6:11PM CST
BTF: 27.34 (+0.45), A: 42.21 (unch), MDGN: 8.00 (-0.45), NU: 52.54 (+1.31), BBY: 40.79 (-0.81), SPB: 93.33 (+0.02), MAR: 84.04 (-0.27), AVID: 15.02 (+0.75), CINF: 54.60 (+0.81), MPC: 102.26 (+2.20), NHF: 12.13 (+0.05), EPM: 5.85 (+0.09), EMC: 26.70 (+0.49), DNY: 21.22 (+0.30), MC: 30.55 (-0.14), TWI: 9.22 (+0.01), SFXE: 4.30 (+0.14), CSCO: 28.44 (+0.18)
Medgenics Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock
GlobeNewswire - Mon Dec 01, 3:02PM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and the patient's own tissue for the treatment of rare and orphan diseases, today announced the completion of an underwritten public offering of 5,893,750 shares of its common stock, including 768,750 shares sold pursuant to the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. All of the shares were offered by Medgenics at a price to the public of $4.10 per share. The gross proceeds from this offering to Medgenics were approximately $24.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Medgenics.
MDGN: 8.00 (-0.45)
Medgenics proposes public offering of common shares
M2 - Wed Nov 26, 6:59AM CST
Gene therapy platform Medgenics (NYSE MKT:MDGN) said on Tuesday that it plans to offer and sell shares of its common stock in an underwritten public offering.
MDGN: 8.00 (-0.45)
Medgenics to Present at 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:01PM CST
Medgenics, Inc. (NYSE MKT:MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that Michael Cola, President and CEO, will participate in a fireside chat discussion at the 26 Annual Piper Jaffray Healthcare Conference in New York.
MDGN: 8.00 (-0.45)
